Rising HPAI (H5N1) spillovers and mounting agricultural losses have renewed interest in bacteriophage therapies, researchers and public‑health agencies report. The U.S. CDC and USDA briefings show spillovers into livestock and rare human infections, while scientists argue phage platforms can address secondary bacterial infections and offer novel vaccine delivery approaches against avian influenza. The coverage synthesizes CDC case counts and APHIS poultry depopulation data with interviews of phage developers exploring phage precision to target antibiotic‑resistant pathogens in influenza‑complicated patients. Companies and public‑health groups are evaluating phage utility both as targeted antimicrobials and as modular platforms for vaccine conception — a two‑track response to zoonotic risk and bacterial co‑infections.